Why Amdocs stock is in focus after earnings, guidance and leadership changes
Amdocs (DOX) is drawing fresh attention after its second quarter results combined higher sales with lower net income and earnings per share, alongside updated 2026 guidance and a planned CFO handover to long time insider Tal Rozenfeld.
See our latest analysis for Amdocs.
The mixed second quarter, revised 2026 guidance and upcoming CFO change appear to be playing out in the share price, with Amdocs at $62.66 and a 7 day share price return of 3.43% but a year to date share price return down 21.83%. The 1 year total shareholder return has declined 29.49%, pointing to pressure on longer term sentiment even as short term momentum has picked up around the dividend affirmation, buyback activity and the incoming CFO’s upcoming investor appearance.
If this kind of post earnings reset has you thinking about where else capital might work harder, it could be worth widening the net and checking out the 20 top founder-led companies
With Amdocs stock down sharply over 1 year and trading at a sizeable discount to some analyst and intrinsic value estimates, the real question for you is whether this reset is a long term opportunity or if the market is already pricing in future growth.
Most Popular Narrative: 30.5% Undervalued
With Amdocs closing at $62.66 against a widely followed fair value estimate of $90.21, the leading narrative frames the stock as materially discounted and heavily shaped by long term earnings assumptions.
The accelerating adoption of cloud, automation, and AI/ML across telecom and media sectors is driving a multi-year wave of IT stack modernization, with Amdocs winning new large-scale modernization and migration deals in cloud, generative AI, and data services, this is expanding its total addressable market and supporting sustained topline revenue growth.
Curious what kind of revenue trajectory and margin profile need to line up for that higher fair value to make sense? The key ingredients are disciplined profitability targets, steady top line expansion, and a future earnings multiple that assumes investors stay comfortable paying up for those cash flows.
Result: Fair Value of $90.21 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on telcos actually following through on cloud and GenAI projects, and on Amdocs managing client concentration without contract delays or renegotiations.
Find out about the key risks to this Amdocs narrative.
Next Steps
If the mixed signals so far leave you on the fence, it helps to move quickly and test the numbers against your own expectations by reviewing the 4 key rewards.
Looking for more investment ideas?
Once you have weighed up Amdocs, it makes sense to compare it with other opportunities so your capital is not missing higher potential elsewhere.
- Target resilience by scanning companies with steady balance sheets and fundamentals using the solid balance sheet and fundamentals stocks screener (46 results).
- Hunt for value by reviewing the screener containing 21 high quality undiscovered gems that may not yet be crowded with attention.
- Prioritize staying power by checking out 66 resilient stocks with low risk scores that score well on risk metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com